Gilde Healthcare appoints Jan Willem Bakker as Head of Investor Relations - Gilde Healthcare

Gilde Healthcare appoints Jan Willem Bakker as Head of Investor Relations

2. September 2024
Utrecht (the Netherlands)

Gilde Healthcare, the transatlantic specialist investment firm, is pleased to announce the addition of Jan Willem Bakker to its team as Partner & Head of Investor Relations.

Jan Willem will focus on Gilde Healthcare’s investor relations activities and contribute to the firm’s capital raising, marketing and communications efforts. With over 20 years of experience in client facing roles in financial services he brings vast experience to benefit existing and new LPs of the Gilde Healthcare platform. “We are pleased to welcome Jan Willem to our Investor Relations and Fundraising team,” said Pieter van der Meer, Managing Partner of Gilde Healthcare. “His extensive track record with institutional investors both as an LP and GP, strong industry relationships, and entrepreneurial mindset will help in strengthening our fundraising strategy and investor relationships. He will be instrumental in the foreseen expansion of our fund platform with impactful private equity strategies.”

Prior to joining Gilde Healthcare, Jan Willem was a partner at Prime Ventures having previously held senior roles at Arcano Partners and Adveq Management AG (now Schroders Capital), during his time at Adveq Jan Willem was a board member of the Dutch Private Equity association (NVP). He began his career in financial services at Kas Bank N.V. “I am very happy to join Gilde Healthcare’s ambitious team and contribute to building out its impactful platform. I look forward to collaborating with existing and prospective investors, investment and finance teams on delivering innovative and successful investment solutions to benefit a range of stakeholders.” said Jan Willem.

About Gilde Healthcare
Gilde Healthcare is a transatlantic specialist investment firm managing over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medtech and therapeutics, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare company SpliceBio announces first patient dosed in Phase 1/2 ASTRA study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease

SB-007 addresses the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations SB-007 is the first dual AAV gene therapy in clinical development for Stargardt disease   SpliceBio,...
13. März 2025

Gilde Healthcare participates in $65 Million financing of Microtransponder to enhance Vivistim adoption for Chronic Stroke Recovery

MicroTransponder®, Inc, today announces a $65 million Series F financing round. MicroTransponder is a fast growing commercial stage stroke company with the FDA-approved Vivistim® Paired VNS™ System. Gilde Healthcare joins the round as new investor,...
12. März 2025

Gilde Healthcare Company Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive Officer

Purespring Therapeutics, a pioneering company focused on transforming the treatment of kidney diseases, today announces the appointment of Haseeb Ahmad as its Chief Executive Officer and member of the Board of Directors effective immediately. Haseeb...
12. März 2025